SB-332235 is a potent, orally bioactive, selective, non-peptide CXCR2 antagonist (inhibitor) with IC50 of 7.7 nM. SB-332235 is 285-fold more selective for CXCR2 than CXCR1. inhibitory activities of SB-332235 in rabbit models of acute and chronic arthritis. SB-332235 inhibits AML cell viability.

Physicochemical Properties

Molecular Formula	C13H10CL3N3O4S
Molecular Weight	410.65
Exact Mass	408.945
CAS #	276702-15-9
PubChem CID	9887803
Appearance	White to off-white solid powder
Density	1.8±0.1 g/cm3
Index of Refraction	1.719
LogP	3.75
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	3
Heavy Atom Count	24
Complexity	559
Defined Atom Stereocenter Count	0
SMILES	ClC=1C=CC(=C(C1S(=O)(N)=O)O)NC(NC2=CC=CC(Cl)=C2Cl)=O
InChi Key	WTLRWOHEKQGKDS-UHFFFAOYSA-N
InChi Code	InChI=1S/C13H10Cl3N3O4S/c14-6-2-1-3-8(10(6)16)18-13(21)19-9-5-4-7(15)12(11(9)20)24(17,22)23/h1-5,20H,(H2,17,22,23)(H2,18,19,21)
Chemical Name	1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea
Synonyms	SB-332235 SB332235 SB 332235
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	SB-332235 (1-100 μM; 48 hours) prevents AML cell lines from being viable [2].
ln Vivo	In the synovial fluid of IL-8-injected knees, SB-332235 (25 mg/kg, po, bid) significantly reduced the total leukocyte counts [1]. SB-332235 (10-25 mg/kg; oral; twice daily for 14 days) inhibits chronic Ag-induced arthritis [1].
Cell Assay	Cell Viability Assay[2] Cell Types: AML Cell Tested Concentrations: 1, 10, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: There was a dose-dependent decrease in proliferation in all cell lines.
Animal Protocol	Animal/Disease Models: Adult female New Zealand white rabbit (chronic OVA-induced arthritis model) [1] Doses: 10, 25 mg/kg Route of Administration: Po; twice a day for 14 days Experimental Results: On day 15, OVA injected The number of white blood cells in the synovial fluid of rabbit knees was Dramatically diminished. The decrease in neutrophils, monocytes and lymphocytes induced by treatment with 25 mg/kg of antagonist was accompanied by a significant decrease in synovial fluid PGE2, LTB4, LTC4 and IL-8 levels.
References	[1]. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002;169(11):6435-6444. [2]. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura]]. Blood. 2015;125(20):3144-3152.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4352 mL	12.1758 mL	24.3516 mL
	5 mM	0.4870 mL	2.4352 mL	4.8703 mL
	10 mM	0.2435 mL	1.2176 mL	2.4352 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.